Nebulization Optimization for Management of Obstructive Airway Disorders: An Expert Review (NOVA-ER)
Main Article Content
Abstract
Background: Nebulization therapy is an essential inhalation technique for managing obstructive airway diseases such as asthma, bronchiectasis, and chronic obstructive pulmonary disease (COPD). In Indian clinical settings, factors such as diverse patient populations, varying disease severity, and healthcare accessibility influence treatment decisions. While clinicians rely on the only available nebulization guideline, its vastness and complexity pose challenges in practical application. Navigating these guidelines and translating recommendations into routine practice remains difficult.
Objective: The NOVA-ER manuscript aims to develop a structured, evidence-based, and expert-driven reference document to streamline nebulization practices in clinical settings and provide guidance for home nebulization.
Methods: A comprehensive review of peer-reviewed literature, clinical guidelines, and systematic reviews was conducted using databases such as PubMed, MEDLINE, and the Cochrane Library, with a focus on studies published in the last ten years to ensure relevance. Additionally, expert opinions were gathered through a structured panel discussion involving specialists in respiratory medicine. A predefined set of questions guided these discussions, and clinical feedback was incorporated to refine recommendations.
Key Takeaways: This manuscript presents stepwise algorithms tailored to individual obstructive airway diseases, facilitating decision-making for both rescue and maintenance therapy. It also helps identify suitable candidates and agents for home nebulization while providing disease-specific guidance for effective nebulization treatment. Furthermore, it integrates expert perspectives with current clinical evidence to optimize nebulization practices.
Conclusion: NOVA-ER serves as a practical tool for clinicians, researchers, and policymakers, offering structured guidance to enhance nebulization practices, support home nebulization, and bridge the gap between evidence-based guidelines and its practical applicability in clinical care which may help improving patient outcomes.
Keywords:
ACO, Asthma, Bronchiectasis, Bronchodilator, Chronic obstructive pulmonary disease, COPD, Nebulization
Article Details
How to Cite
DHAR, Raja et al.
Nebulization Optimization for Management of Obstructive Airway Disorders: An Expert Review (NOVA-ER).
Medical Research Archives, [S.l.], v. 13, n. 4, apr. 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6377>. Date accessed: 15 may 2025.
doi: https://doi.org/10.18103/mra.v13i4.6377.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Chronic obstructive pulmonary disease (COPD). WHO Newsroom: March 16, 2023. https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) Accessed August 9, 2024
2. Jarhyan P, Hutchinson A, Khaw D, Prabhakaran D, Mohan S. Prevalence of chronic obstructive pulmonary disease and chronic bronchitis in eight countries: a systematic review and meta-analysis. Bull World Health Organ. 2022;100(3):216-30. doi:10.2471/BLT.21.286870
3. Singh S, Salvi S, Mangal DK, Singh M, Awasthi S, Mahesh PA, et al. Prevalence, time trends and treatment practices of asthma in India: The Global Asthma Network study. ERJ Open Res. 2022;8(2):00528-2021. doi:10.1183/23120541.00528-2021
4. Yeo Y, Lee H, Ryu J, Chung SJ, Park TS, Park DW, et al. Additive effects of coexisting respiratory comorbidities on overall or respiratory mortality in patients with asthma: a national cohort study. Sci Rep. 2022;12:8105. doi:10.1038/s41598-022-12103-w
5. Mekov E, Nuñez A, Sin DD, Ichinose M, Rhee CK, Maselli DJ, et al. Update on Asthma–COPD Overlap (ACO): A narrative review. Int J Chron Obstruct Pulmon Dis. 2021;16:1783-99. doi:10.2147/COPD.S312560
6. Martínez García MÁ, Soriano JB. Asthma, bronchiectasis, and chronic obstructive pulmonary disease: the Bermuda Triangle of the airways. Chin Med J. 2022;135(12):1390-3. doi:10.1097/CM9.0000000000002225
7. Dhar R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnakar R, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Glob Health. 2019;7(9):e1269-79. doi:10.1016/S2214-109X(19)30327-4
8. Sharma BB, Singh S, Sharma KK, Sharma AK, Suraj KP, Mahmood T, et al. Proportionate clinical burden of respiratory diseases in Indian outdoor services and its relationship with seasonal transitions and risk factors: The results of SWORD survey. Hadda V, editor. Plos One. 2022;17(8):e0268216. doi:10.1371/journal.pone.0268216
9. Wu Y, Zhang J. Standardized inhalation capability assessment: A key to optimal inhaler selection for inhalation therapy. J Transl Intern Med. 11(1):26-9. doi:10.2478/jtim-2022-0073
10. Zhou XL, Zhao LY. Comparison of clinical features and outcomes for asthma-COPD overlap syndrome vs. COPD patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(3):1495-510. doi:10.26355/eurrev_2021 02_24857
11. Shukla D, Chhabra D, Kumar Sharma R, Luhadia D, Sharma D, Luhadia D, et al. Prevalence and demographical variation of asthma COPD overlap (ACO) in previously diagnosed chronic obstructive pulmonary disease patients of Southern Rajasthan: A cross-sectional study. Int J Adv Res Med. 2021;3:523-5. doi:10.22271/27069567.2021.v3.i1i.195
12. Akilandeswari SH, Kavitha B, Sudhakaran J, Rajkanth K. A study on "Prevalence of COPD overlap in asthma patients–hospital based cross sectional study." Int J Sci Res. 2021;42-4. doi:10.36106/ijsr/1907079
13. Alhaddad B, Smith FJ, Robertson T, Watman G, Taylor KMG. Patients' practices and experiences of using nebuliser therapy in the management of COPD at home. BMJ Open Respir Res. 2015;2(1):e000076. doi:10.1136/bmjresp-2014-000076
14. LaCrone ME, Buening N, Paul N. A retrospective review of an inhaler to nebulizer therapeutic interchange program across a health system. J Pharm Pract. 2023;36(5):1211-6. doi:10.1177/08971900221101761
15. Tashkin DP, Lipworth B, Brattsand R. Benefit: risk profile of budesonide in obstructive airways disease. Drugs. 2019;79(16):1757-75. doi:10.1007/s40265-019-01198-7
16. Dhand R, Dolovich M, Chipps B, Myers TR, Restrepo R, Farrar JR. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58-72. doi:10.3109/15412555.2011.630047
17. Santus P, Radovanovic D, Cristiano A, Valenti V, Rizzi M. Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease. Drug Des Devel Ther. 2017;11:3257-71. doi:10.2147/DDDT.S135377
18. Plaza, V., Giner, J., Rodrigo, G. J., Dolovich, M. B., & Sanchis, J. (2018). Errors in the Use of Inhalers by Health Care Professionals: A Systematic Review. The Journal of Allergy and Clinical Immunology: In Practice, 6(3), 987–995. doi:10.1016/j.jaip.2017. 12.032
19. van Geffen WH, Carpaij OA, Westbroek LF, Seigers D, Niemeijer A, Vonk JM, et al. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial. Respir Med. 2020;171:106064. doi:10.1016/j.rmed.2020.106064
20. Sriram KB, Percival M. Suboptimal inhaler medication adherence and incorrect technique are common among chronic obstructive pulmonary disease patients. Chron Respir Dis. 2016;13(1):13–22. doi: 10.1177/1479972315 606313
21. Swarnakar R, Dhar R. Call to action: Addressing asthma diagnosis and treatment gaps in India. Lung India. 2024;41(3):209–16. doi: 10.4103/lungindia. lungindia_518_23
22. Kocks J, Bosnic-Anticevich S, Cooten J, Correia de Sousa J, Cvetkovski B, Dekhuijzen R, et al. Identifying critical inhalation technique errors in Dry Powder Inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study. BMC Pulm Med. 2023;23(1):302. doi:10.1186/s12890-023-02566-6
23. Schreiber J, Sonnenburg T, Luecke E. Inhaler devices in asthma and COPD patients - a prospective cross-sectional study on inhaler preferences and error rates. BMC Pulm Med. 2020;20(1):222. doi:10.1186/s12890-020-01246-z
24. Akhoon N, S. Brashier DB. A study to monitor errors in use of inhalation devices in patients of mild-to-moderate bronchial asthma in a tertiary care hospital in Eastern India. Perspect Clin Res. 2022;13(1):17-24. doi:10.4103/picr.PICR_210_19
25. Heo YA. Budesonide/Glycopyrronium/Formoterol: A Review in COPD. Drugs. 2021;81(12):1411-22. doi:10.1007/s40265-021-01562-6
26. Inhalations for bronchitis: Types and how they work. Medical News Today: August 15, 2023. https://www.medicalnewstoday.com/articles/inhalations-for-bronchitis Accessed August 9, 2024.
27. Albert RH. Diagnosis and treatment of acute bronchitis. Am Fam Physician. 2010;82(11):1345-50. https://www.aafp.org/pubs/afp/issues/2010/1201/p1345.html
28. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(3):228-37. doi:10.1164/rccm.201210-1843CI
29. Tashkin DP, Ozol-Godfrey A, Sharma S, Sanjar S. Effect of SGRQ-defined chronic bronchitis at baseline on treatment outcomes in patients with COPD receiving nebulized glycopyrrolate. Int J Chron Obstruct Pulmon Dis. 2021;16:945-55. doi:10.2147/COPD.S304182
30. van Geffen WH, Douma WR, Slebos DJ, Kerstjens HAM. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev. 2016;2016(8):CD011826. doi:10.1002/14651858.CD011826.pub2
31. House SA, Gadomski AM, Ralston SL. Evaluating the placebo status of nebulized normal saline in patients with acute viral bronchiolitis: a systematic review and meta-analysis. JAMA Pediatr. 2020;174(3):250-9. doi; 10.1001/jamapediatrics.2019.5195
32. Huang C, Kuo S, Lin L, Yang Y. The efficacy of N -acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis. Ther Adv Respir Dis. 2023;17:175346662311585. doi:10.1177/17534666231158563
33. Otu A, Langridge P, Denning DW. Nebulised N-acetylcysteine for unresponsive bronchial obstruction in allergic brochopulmonary aspergillosis: a case series and review of the literature. J Fungi. 2018;4(4):117. doi:10.3390/jof4040117
34. Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD Executive Summary. Eur Respir J. 2023;61(4):2300239. doi:10.1183/13993003.00239-2023
35. Donohue J, Betts K, Du EX, Altman P, Goyal P, Keininger D, et al. Comparative efficacy of long-acting beta-2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:367-81. doi:10.2147/COPD.S119908
36. Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta‐analysis. Cochrane Database Syst Rev. 2018;2018(12):CD012620. doi:10.1002/14651858.CD012620.pub2
37. Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicenter, phase 3 randomized controlled trial. Lancet Respir Med. 2018;6(10):747-58. doi:10.1016/S2213-2600(18)30327-8
38. Gunen H, Kokturk N, Naycı S, Ozkaya S, Yıldız BP, Turan O, et al. The CO-MIND Study: Chronic Obstructive Pulmonary Disease Management in Daily Practice and Its Implications for Improved Outcomes According to GOLD 2019 Perspective. Int J Chron Obstruct Pulmon Dis. 2022;17:1883-95. doi:10.2147/COPD.S372439
39. Berry RB, Shinto RA, Wong FH, Despars JA, Light RW. Nebulizer vs spacer for bronchodilator delivery in patients hospitalized for acute exacerbations of COPD. Chest. 1989;96(6):1241-6. doi:10.1378/chest.96.6.1241
40. Chen Y, Liu Y, Zhang J, Yao W, Yang J, Li F, et al. Comparison of the Clinical Outcomes Between Nebulized and Systemic Corticosteroids in the Treatment of Acute Exacerbation of COPD in China (CONTAIN Study): A Post Hoc Analysis. Int J Chron Obstruct Pulmon Dis. 2020;15:2343-53. doi:10.2147/COPD.S255475
41. Vijay J, Raju A, Joseph A, Ramesh A, Haridas N, Vijayan M. A prospective study to assess the impact of formoterol and budesonide nebulization as add on therapy in the management of acute exacerbation of COPD in a tertiary care hospital. Res J Pharm Technol. 2021;14(3):1723-8.
doi:10.5958/0974-360X.2021.00307.3
42. Kulalert P, Phinyo P, Patumanond J, Smathakanee C, Chuenjit W, Nanthapisal S. Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysis. Asthma Res Pract. 2020;6:6. doi:10.1186/s40733-020-00059-5
43. Talwar D, Bendre S. Health-related effects of home nebulization with glycopyrronium on difficult-to-treat asthma: post-hoc analyses of an observational study. Interact J Med Res. 2020;9(2):e17863. doi:10.2196/17863
44. Rodrigo GJ, Neffen H, Colodenco FD, Castro-Rodriguez JA. Formoterol for acute asthma in the emergency department: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2010;104(3):247-52. doi:10.1016/j.anai.2009.11.064
45. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma. N Engl J Med. 2000;343(5):332-6. doi:10.1056/NEJM200008033430504
46. Hill JM. Nebulised corticosteroids in the treatment of patients with asthma. Thorax. 1999;54(8):661-3. doi:10.1136/thx.54.8.661
47. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martínez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations: SMART vs. BUD/FORM and SAL/FLU. Int J Clin Pract. 2007;61(5):725-36. doi:10.1111/j.1742-1241.2007.01338.x
48. Marghli S, Bouhamed C, Sghaier A, Chebbi N, Dlala I, Bettout S, et al. Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial. BMC Emerg Med. 2022;22(1):134. doi:10.1186/s12873-022-00691-9
49. Mogilappa R, Mourya Gupta AS, Narasimha MP. Comparison of improvement in clinical, spirometric and oxygenation parameters after Nebulization with levosalbutamol and formoterol-budesonide in moderate to severe asthma. J Evid Based Med Healthc. 2018;5(39):2801-5. doi:10.18410/jebmh/2018/573
50. Cusack RP, Satia I, O'Byrne PM. Asthma maintenance and reliever therapy: Should this be the standard of care? Ann Allergy Asthma Immunol. 2020;125(2): 150-5. doi:10.1016/j.anai.2020.04.009
51. Pocket Guide for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf Accessed August 9, 2024
52. Albertson TE, Sutter ME, Chan AL. The acute management of asthma. Clin Rev Allergy Immunol. 2015;48(1):114-25. doi:10.1007/s12016-014-8448-5
53. Duong TN, Zeki AA, Louie S. Medical management of hospitalized patients with asthma or chronic obstructive pulmonary disease. Hosp Med Clin. 2017;6(4):437. doi:10.1016/j.ehmc.2017.05.002
54. Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome and disease heterogeneity. Lancet Lond Engl. 2018;392(10150):880. doi:10.1016/S0140-6736(18)31767-7
55. Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):S1-S69. doi:10.1136/thoraxjnl-2018-212463
56. Chang AB, Fortescue R, Grimwood K, Alexopoulou E, Bell L, Boyd J, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021;58(2):2002990. doi:10.1183/13993003.02990-2020
57. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi:10.1183/13993003.00629-2017
58. Shehzad MI, Mannan MAU, Alam M, Rauf A, Sharif MI. Airway clearance in bronchiectasis: A randomized control trial of N-Acetylcysteine with 3% hypertonic saline. J Islamabad Med Dent Coll. 2019;8(3):146-50. doi:10.35787/jimdc.v8i3.389
59. Elborn JS, Blasi F, Haworth CS, Ballmann M, Tiddens HAWM, Murris-Espin M, et al. Bronchiectasis and inhaled tobramycin: A literature review. Respir Med. 2022;192:106728. doi:10.1016/j.rmed.2021.106728
60. Orriols R, Hernando R, Ferrer A, Terradas S, Montoro B. Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis. Respir Int Rev Thorac Dis. 2015;90(4):299-305. doi:10.1159/000438490
61. Vendrell M, Muñoz G, Gracia J. Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis. Open Respir Med J. 2015;9:30-6. doi:10.2174/1874306401509010030
62. Tabernero Huguet E, Gil Alaña P, Alkiza Basañez R, Hernández Gil A, Garros Garay J, Artola Igarza JL. Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection. Rev Espanola Geriatr Gerontol. 2015;50(3):111-5. doi:10.1016/j.regg.2014.09.005
63. Steinfort DP, Steinfort C. Effect of long‐term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J. 2007;37(7):495-8. doi:10.1111/j.1445-5994.2007 .01404.x
64. Dhar R, Anwar GA, Bourke SC, Doherty L, Middleton P, Ward C, et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax. 2010;65(6):553. doi:10.1136/thx.2008.112284
65. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection. Am J Respir Crit Care Med. 2014;189(8):975-82. doi:10.1164/rccm.201312-2208OC
66. de la Rosa-Carrillo D, Suárez-Cuartín G, Golpe R, Máiz Carro L, Martinez-Garcia MA. Inhaled colistimethate sodium in the management of patients with bronchiectasis infected by pseudomonas aeruginosa: A narrative review of current evidence. Infect Drug Resist. 2022;15:7271-92. doi:10.2147/IDR.S318173
67. Martinez-Garcia M, Oscullo G, Barreiro E, Cuenca S, Cervera A, Padilla A, et al. Inhaled dry powder antibiotics in patients with non-cystic fibrosis bronchiectasis: Efficacy and safety in a real-life study. J Clin Med. 2020;9(7):2317. doi:10.3390/jcm9072317
68. Littlewood JM, Koch C, Lambert PA, Høiby N, Elborn JS, Conway SP, et al. A ten-year review of colomycin. Respir Med. 2000;94(7):632-40. doi:10.1053/rmed.2000.0834
69. Lee AL. Physiotherapy management of bronchiectasis in adults. J Physiother. 2023;69(1):7-14. doi:10.1016/j.jphys.2022.11.013
70. Qi Q, Ailiyaer Y, Liu R, Zhang Y, Li C, Liu M, et al. Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respir Res. 2019;20(1):73. doi:10.1186/s12931-019-1042-x
71. Papaiwannou A, Zarogoulidis P, Porpodis K, Spyratos D, Kioumis I, Pitsiou G, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. J Thorac Dis. 2014;6(Suppl 1):S146-S51. doi:10.3978/j.issn.2072-1439.2014.03.04
72. Sin DD. Asthma-COPD Overlap Syndrome: What we know and what we don't. Tuberc Respir Dis. 2017;80(1):11-20. doi:10.4046/trd.2017.80.1.11
73. Agarwal R, Sehgal IS, Muthu V, Denning DW, Chakrabarti A, Soundappan K, et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J. 2024;63(4):2400061. doi:10.1183/13993003.00061-2024
74. Crimi C, Ferri S, Campisi R, Crimi N. The Link between asthma and bronchiectasis: State of the art. Respiration. 2020;99(6):463-76. doi:10.1159/000507228
75. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Section 4, Stepwise Approach for Managing Asthma in Youths ≥12 Years of Age and Adults. National Heart, Lung, and Blood Institute (US). 2007:328-53. https://www.ncbi.nlm.nih.gov/books/n/asthma3/pdf
76. Martínez-García MÁ, Oscullo G, García-Ortega A, Matera MG, Rogliani P, Cazzola M. Inhaled corticosteroids in adults with non-cystic fibrosis bronchiectasis: from bench to bedside. A narrative review. Drugs. 2022;82(14):1453. doi:10.1007/s40265-022-01785-1
77. Muñoz G, Gracia J, Buxó M, Alvarez A, Vendrell M. Long-term benefits of airway clearance in bronchiectasis: A randomised placebo-controlled trial. Eur Respir J. 2018;51(1):1701926. doi:10.1183/13993003.01926-2017
78. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63(5):e61-111. doi:10.1093/cid/ciw353
79. Dhand R. How should aerosols be delivered during invasive mechanical ventilation? Respir Care. 2017;62(10):1343-67. doi:10.4187/respcare.05803
80. Balzano G, Battiloro R, Biraghi M, Stefanelli F, Fuschillo S, Gaudiosi C, et al. Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients with chronic airflow obstruction: metered dose inhaler versus jet nebulizer. J Aerosol Med. 2000;13(1):25-33. doi:10.1089/jam.2000.13.25
81. O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MCP, Bernstein A. A long-term prospective assessment of home nebulizer treatment. Respir Med. 1992;86(4):317-25. doi:10.1016/S0954-6111(06)80031-4
82. Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305-11. doi:10.1513/AnnalsATS.201611-903OC
83. Chinese College of Emergency Physicians (CCEP), Emergency Committee of PLA, Beijing Society for Emergency Medicine, Chinese Emergency Medicine. Expert expert opinion on nebulization therapy in pre-hospital and in-hospital emergency care. Ann Transl Med. 2019;7(18):487-87. doi:10.21037/atm.2019.09.44
2. Jarhyan P, Hutchinson A, Khaw D, Prabhakaran D, Mohan S. Prevalence of chronic obstructive pulmonary disease and chronic bronchitis in eight countries: a systematic review and meta-analysis. Bull World Health Organ. 2022;100(3):216-30. doi:10.2471/BLT.21.286870
3. Singh S, Salvi S, Mangal DK, Singh M, Awasthi S, Mahesh PA, et al. Prevalence, time trends and treatment practices of asthma in India: The Global Asthma Network study. ERJ Open Res. 2022;8(2):00528-2021. doi:10.1183/23120541.00528-2021
4. Yeo Y, Lee H, Ryu J, Chung SJ, Park TS, Park DW, et al. Additive effects of coexisting respiratory comorbidities on overall or respiratory mortality in patients with asthma: a national cohort study. Sci Rep. 2022;12:8105. doi:10.1038/s41598-022-12103-w
5. Mekov E, Nuñez A, Sin DD, Ichinose M, Rhee CK, Maselli DJ, et al. Update on Asthma–COPD Overlap (ACO): A narrative review. Int J Chron Obstruct Pulmon Dis. 2021;16:1783-99. doi:10.2147/COPD.S312560
6. Martínez García MÁ, Soriano JB. Asthma, bronchiectasis, and chronic obstructive pulmonary disease: the Bermuda Triangle of the airways. Chin Med J. 2022;135(12):1390-3. doi:10.1097/CM9.0000000000002225
7. Dhar R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnakar R, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Glob Health. 2019;7(9):e1269-79. doi:10.1016/S2214-109X(19)30327-4
8. Sharma BB, Singh S, Sharma KK, Sharma AK, Suraj KP, Mahmood T, et al. Proportionate clinical burden of respiratory diseases in Indian outdoor services and its relationship with seasonal transitions and risk factors: The results of SWORD survey. Hadda V, editor. Plos One. 2022;17(8):e0268216. doi:10.1371/journal.pone.0268216
9. Wu Y, Zhang J. Standardized inhalation capability assessment: A key to optimal inhaler selection for inhalation therapy. J Transl Intern Med. 11(1):26-9. doi:10.2478/jtim-2022-0073
10. Zhou XL, Zhao LY. Comparison of clinical features and outcomes for asthma-COPD overlap syndrome vs. COPD patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(3):1495-510. doi:10.26355/eurrev_2021 02_24857
11. Shukla D, Chhabra D, Kumar Sharma R, Luhadia D, Sharma D, Luhadia D, et al. Prevalence and demographical variation of asthma COPD overlap (ACO) in previously diagnosed chronic obstructive pulmonary disease patients of Southern Rajasthan: A cross-sectional study. Int J Adv Res Med. 2021;3:523-5. doi:10.22271/27069567.2021.v3.i1i.195
12. Akilandeswari SH, Kavitha B, Sudhakaran J, Rajkanth K. A study on "Prevalence of COPD overlap in asthma patients–hospital based cross sectional study." Int J Sci Res. 2021;42-4. doi:10.36106/ijsr/1907079
13. Alhaddad B, Smith FJ, Robertson T, Watman G, Taylor KMG. Patients' practices and experiences of using nebuliser therapy in the management of COPD at home. BMJ Open Respir Res. 2015;2(1):e000076. doi:10.1136/bmjresp-2014-000076
14. LaCrone ME, Buening N, Paul N. A retrospective review of an inhaler to nebulizer therapeutic interchange program across a health system. J Pharm Pract. 2023;36(5):1211-6. doi:10.1177/08971900221101761
15. Tashkin DP, Lipworth B, Brattsand R. Benefit: risk profile of budesonide in obstructive airways disease. Drugs. 2019;79(16):1757-75. doi:10.1007/s40265-019-01198-7
16. Dhand R, Dolovich M, Chipps B, Myers TR, Restrepo R, Farrar JR. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD. 2012;9(1):58-72. doi:10.3109/15412555.2011.630047
17. Santus P, Radovanovic D, Cristiano A, Valenti V, Rizzi M. Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease. Drug Des Devel Ther. 2017;11:3257-71. doi:10.2147/DDDT.S135377
18. Plaza, V., Giner, J., Rodrigo, G. J., Dolovich, M. B., & Sanchis, J. (2018). Errors in the Use of Inhalers by Health Care Professionals: A Systematic Review. The Journal of Allergy and Clinical Immunology: In Practice, 6(3), 987–995. doi:10.1016/j.jaip.2017. 12.032
19. van Geffen WH, Carpaij OA, Westbroek LF, Seigers D, Niemeijer A, Vonk JM, et al. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial. Respir Med. 2020;171:106064. doi:10.1016/j.rmed.2020.106064
20. Sriram KB, Percival M. Suboptimal inhaler medication adherence and incorrect technique are common among chronic obstructive pulmonary disease patients. Chron Respir Dis. 2016;13(1):13–22. doi: 10.1177/1479972315 606313
21. Swarnakar R, Dhar R. Call to action: Addressing asthma diagnosis and treatment gaps in India. Lung India. 2024;41(3):209–16. doi: 10.4103/lungindia. lungindia_518_23
22. Kocks J, Bosnic-Anticevich S, Cooten J, Correia de Sousa J, Cvetkovski B, Dekhuijzen R, et al. Identifying critical inhalation technique errors in Dry Powder Inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study. BMC Pulm Med. 2023;23(1):302. doi:10.1186/s12890-023-02566-6
23. Schreiber J, Sonnenburg T, Luecke E. Inhaler devices in asthma and COPD patients - a prospective cross-sectional study on inhaler preferences and error rates. BMC Pulm Med. 2020;20(1):222. doi:10.1186/s12890-020-01246-z
24. Akhoon N, S. Brashier DB. A study to monitor errors in use of inhalation devices in patients of mild-to-moderate bronchial asthma in a tertiary care hospital in Eastern India. Perspect Clin Res. 2022;13(1):17-24. doi:10.4103/picr.PICR_210_19
25. Heo YA. Budesonide/Glycopyrronium/Formoterol: A Review in COPD. Drugs. 2021;81(12):1411-22. doi:10.1007/s40265-021-01562-6
26. Inhalations for bronchitis: Types and how they work. Medical News Today: August 15, 2023. https://www.medicalnewstoday.com/articles/inhalations-for-bronchitis Accessed August 9, 2024.
27. Albert RH. Diagnosis and treatment of acute bronchitis. Am Fam Physician. 2010;82(11):1345-50. https://www.aafp.org/pubs/afp/issues/2010/1201/p1345.html
28. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(3):228-37. doi:10.1164/rccm.201210-1843CI
29. Tashkin DP, Ozol-Godfrey A, Sharma S, Sanjar S. Effect of SGRQ-defined chronic bronchitis at baseline on treatment outcomes in patients with COPD receiving nebulized glycopyrrolate. Int J Chron Obstruct Pulmon Dis. 2021;16:945-55. doi:10.2147/COPD.S304182
30. van Geffen WH, Douma WR, Slebos DJ, Kerstjens HAM. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. Cochrane Database Syst Rev. 2016;2016(8):CD011826. doi:10.1002/14651858.CD011826.pub2
31. House SA, Gadomski AM, Ralston SL. Evaluating the placebo status of nebulized normal saline in patients with acute viral bronchiolitis: a systematic review and meta-analysis. JAMA Pediatr. 2020;174(3):250-9. doi; 10.1001/jamapediatrics.2019.5195
32. Huang C, Kuo S, Lin L, Yang Y. The efficacy of N -acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis. Ther Adv Respir Dis. 2023;17:175346662311585. doi:10.1177/17534666231158563
33. Otu A, Langridge P, Denning DW. Nebulised N-acetylcysteine for unresponsive bronchial obstruction in allergic brochopulmonary aspergillosis: a case series and review of the literature. J Fungi. 2018;4(4):117. doi:10.3390/jof4040117
34. Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD Executive Summary. Eur Respir J. 2023;61(4):2300239. doi:10.1183/13993003.00239-2023
35. Donohue J, Betts K, Du EX, Altman P, Goyal P, Keininger D, et al. Comparative efficacy of long-acting beta-2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:367-81. doi:10.2147/COPD.S119908
36. Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta‐analysis. Cochrane Database Syst Rev. 2018;2018(12):CD012620. doi:10.1002/14651858.CD012620.pub2
37. Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicenter, phase 3 randomized controlled trial. Lancet Respir Med. 2018;6(10):747-58. doi:10.1016/S2213-2600(18)30327-8
38. Gunen H, Kokturk N, Naycı S, Ozkaya S, Yıldız BP, Turan O, et al. The CO-MIND Study: Chronic Obstructive Pulmonary Disease Management in Daily Practice and Its Implications for Improved Outcomes According to GOLD 2019 Perspective. Int J Chron Obstruct Pulmon Dis. 2022;17:1883-95. doi:10.2147/COPD.S372439
39. Berry RB, Shinto RA, Wong FH, Despars JA, Light RW. Nebulizer vs spacer for bronchodilator delivery in patients hospitalized for acute exacerbations of COPD. Chest. 1989;96(6):1241-6. doi:10.1378/chest.96.6.1241
40. Chen Y, Liu Y, Zhang J, Yao W, Yang J, Li F, et al. Comparison of the Clinical Outcomes Between Nebulized and Systemic Corticosteroids in the Treatment of Acute Exacerbation of COPD in China (CONTAIN Study): A Post Hoc Analysis. Int J Chron Obstruct Pulmon Dis. 2020;15:2343-53. doi:10.2147/COPD.S255475
41. Vijay J, Raju A, Joseph A, Ramesh A, Haridas N, Vijayan M. A prospective study to assess the impact of formoterol and budesonide nebulization as add on therapy in the management of acute exacerbation of COPD in a tertiary care hospital. Res J Pharm Technol. 2021;14(3):1723-8.
doi:10.5958/0974-360X.2021.00307.3
42. Kulalert P, Phinyo P, Patumanond J, Smathakanee C, Chuenjit W, Nanthapisal S. Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysis. Asthma Res Pract. 2020;6:6. doi:10.1186/s40733-020-00059-5
43. Talwar D, Bendre S. Health-related effects of home nebulization with glycopyrronium on difficult-to-treat asthma: post-hoc analyses of an observational study. Interact J Med Res. 2020;9(2):e17863. doi:10.2196/17863
44. Rodrigo GJ, Neffen H, Colodenco FD, Castro-Rodriguez JA. Formoterol for acute asthma in the emergency department: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2010;104(3):247-52. doi:10.1016/j.anai.2009.11.064
45. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-Dose Inhaled Corticosteroids and the Prevention of Death from Asthma. N Engl J Med. 2000;343(5):332-6. doi:10.1056/NEJM200008033430504
46. Hill JM. Nebulised corticosteroids in the treatment of patients with asthma. Thorax. 1999;54(8):661-3. doi:10.1136/thx.54.8.661
47. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martínez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations: SMART vs. BUD/FORM and SAL/FLU. Int J Clin Pract. 2007;61(5):725-36. doi:10.1111/j.1742-1241.2007.01338.x
48. Marghli S, Bouhamed C, Sghaier A, Chebbi N, Dlala I, Bettout S, et al. Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial. BMC Emerg Med. 2022;22(1):134. doi:10.1186/s12873-022-00691-9
49. Mogilappa R, Mourya Gupta AS, Narasimha MP. Comparison of improvement in clinical, spirometric and oxygenation parameters after Nebulization with levosalbutamol and formoterol-budesonide in moderate to severe asthma. J Evid Based Med Healthc. 2018;5(39):2801-5. doi:10.18410/jebmh/2018/573
50. Cusack RP, Satia I, O'Byrne PM. Asthma maintenance and reliever therapy: Should this be the standard of care? Ann Allergy Asthma Immunol. 2020;125(2): 150-5. doi:10.1016/j.anai.2020.04.009
51. Pocket Guide for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf Accessed August 9, 2024
52. Albertson TE, Sutter ME, Chan AL. The acute management of asthma. Clin Rev Allergy Immunol. 2015;48(1):114-25. doi:10.1007/s12016-014-8448-5
53. Duong TN, Zeki AA, Louie S. Medical management of hospitalized patients with asthma or chronic obstructive pulmonary disease. Hosp Med Clin. 2017;6(4):437. doi:10.1016/j.ehmc.2017.05.002
54. Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome and disease heterogeneity. Lancet Lond Engl. 2018;392(10150):880. doi:10.1016/S0140-6736(18)31767-7
55. Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):S1-S69. doi:10.1136/thoraxjnl-2018-212463
56. Chang AB, Fortescue R, Grimwood K, Alexopoulou E, Bell L, Boyd J, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021;58(2):2002990. doi:10.1183/13993003.02990-2020
57. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi:10.1183/13993003.00629-2017
58. Shehzad MI, Mannan MAU, Alam M, Rauf A, Sharif MI. Airway clearance in bronchiectasis: A randomized control trial of N-Acetylcysteine with 3% hypertonic saline. J Islamabad Med Dent Coll. 2019;8(3):146-50. doi:10.35787/jimdc.v8i3.389
59. Elborn JS, Blasi F, Haworth CS, Ballmann M, Tiddens HAWM, Murris-Espin M, et al. Bronchiectasis and inhaled tobramycin: A literature review. Respir Med. 2022;192:106728. doi:10.1016/j.rmed.2021.106728
60. Orriols R, Hernando R, Ferrer A, Terradas S, Montoro B. Eradication Therapy against Pseudomonas aeruginosa in Non-Cystic Fibrosis Bronchiectasis. Respir Int Rev Thorac Dis. 2015;90(4):299-305. doi:10.1159/000438490
61. Vendrell M, Muñoz G, Gracia J. Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis. Open Respir Med J. 2015;9:30-6. doi:10.2174/1874306401509010030
62. Tabernero Huguet E, Gil Alaña P, Alkiza Basañez R, Hernández Gil A, Garros Garay J, Artola Igarza JL. Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection. Rev Espanola Geriatr Gerontol. 2015;50(3):111-5. doi:10.1016/j.regg.2014.09.005
63. Steinfort DP, Steinfort C. Effect of long‐term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J. 2007;37(7):495-8. doi:10.1111/j.1445-5994.2007 .01404.x
64. Dhar R, Anwar GA, Bourke SC, Doherty L, Middleton P, Ward C, et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax. 2010;65(6):553. doi:10.1136/thx.2008.112284
65. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection. Am J Respir Crit Care Med. 2014;189(8):975-82. doi:10.1164/rccm.201312-2208OC
66. de la Rosa-Carrillo D, Suárez-Cuartín G, Golpe R, Máiz Carro L, Martinez-Garcia MA. Inhaled colistimethate sodium in the management of patients with bronchiectasis infected by pseudomonas aeruginosa: A narrative review of current evidence. Infect Drug Resist. 2022;15:7271-92. doi:10.2147/IDR.S318173
67. Martinez-Garcia M, Oscullo G, Barreiro E, Cuenca S, Cervera A, Padilla A, et al. Inhaled dry powder antibiotics in patients with non-cystic fibrosis bronchiectasis: Efficacy and safety in a real-life study. J Clin Med. 2020;9(7):2317. doi:10.3390/jcm9072317
68. Littlewood JM, Koch C, Lambert PA, Høiby N, Elborn JS, Conway SP, et al. A ten-year review of colomycin. Respir Med. 2000;94(7):632-40. doi:10.1053/rmed.2000.0834
69. Lee AL. Physiotherapy management of bronchiectasis in adults. J Physiother. 2023;69(1):7-14. doi:10.1016/j.jphys.2022.11.013
70. Qi Q, Ailiyaer Y, Liu R, Zhang Y, Li C, Liu M, et al. Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respir Res. 2019;20(1):73. doi:10.1186/s12931-019-1042-x
71. Papaiwannou A, Zarogoulidis P, Porpodis K, Spyratos D, Kioumis I, Pitsiou G, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. J Thorac Dis. 2014;6(Suppl 1):S146-S51. doi:10.3978/j.issn.2072-1439.2014.03.04
72. Sin DD. Asthma-COPD Overlap Syndrome: What we know and what we don't. Tuberc Respir Dis. 2017;80(1):11-20. doi:10.4046/trd.2017.80.1.11
73. Agarwal R, Sehgal IS, Muthu V, Denning DW, Chakrabarti A, Soundappan K, et al. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J. 2024;63(4):2400061. doi:10.1183/13993003.00061-2024
74. Crimi C, Ferri S, Campisi R, Crimi N. The Link between asthma and bronchiectasis: State of the art. Respiration. 2020;99(6):463-76. doi:10.1159/000507228
75. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Section 4, Stepwise Approach for Managing Asthma in Youths ≥12 Years of Age and Adults. National Heart, Lung, and Blood Institute (US). 2007:328-53. https://www.ncbi.nlm.nih.gov/books/n/asthma3/pdf
76. Martínez-García MÁ, Oscullo G, García-Ortega A, Matera MG, Rogliani P, Cazzola M. Inhaled corticosteroids in adults with non-cystic fibrosis bronchiectasis: from bench to bedside. A narrative review. Drugs. 2022;82(14):1453. doi:10.1007/s40265-022-01785-1
77. Muñoz G, Gracia J, Buxó M, Alvarez A, Vendrell M. Long-term benefits of airway clearance in bronchiectasis: A randomised placebo-controlled trial. Eur Respir J. 2018;51(1):1701926. doi:10.1183/13993003.01926-2017
78. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63(5):e61-111. doi:10.1093/cid/ciw353
79. Dhand R. How should aerosols be delivered during invasive mechanical ventilation? Respir Care. 2017;62(10):1343-67. doi:10.4187/respcare.05803
80. Balzano G, Battiloro R, Biraghi M, Stefanelli F, Fuschillo S, Gaudiosi C, et al. Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients with chronic airflow obstruction: metered dose inhaler versus jet nebulizer. J Aerosol Med. 2000;13(1):25-33. doi:10.1089/jam.2000.13.25
81. O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MCP, Bernstein A. A long-term prospective assessment of home nebulizer treatment. Respir Med. 1992;86(4):317-25. doi:10.1016/S0954-6111(06)80031-4
82. Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc. 2017;14(8):1305-11. doi:10.1513/AnnalsATS.201611-903OC
83. Chinese College of Emergency Physicians (CCEP), Emergency Committee of PLA, Beijing Society for Emergency Medicine, Chinese Emergency Medicine. Expert expert opinion on nebulization therapy in pre-hospital and in-hospital emergency care. Ann Transl Med. 2019;7(18):487-87. doi:10.21037/atm.2019.09.44